CN114641473A - Brd9双官能团降解剂及其使用方法 - Google Patents

Brd9双官能团降解剂及其使用方法 Download PDF

Info

Publication number
CN114641473A
CN114641473A CN202080061458.1A CN202080061458A CN114641473A CN 114641473 A CN114641473 A CN 114641473A CN 202080061458 A CN202080061458 A CN 202080061458A CN 114641473 A CN114641473 A CN 114641473A
Authority
CN
China
Prior art keywords
group
compound
alkylene
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080061458.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·洛伯
M·森齐克
陈昕
M-L·古德
E·M·哈林顿
G·J·霍林沃思
A·武尔佩蒂
T·佐勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72915891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114641473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN114641473A publication Critical patent/CN114641473A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080061458.1A 2019-09-16 2020-09-14 Brd9双官能团降解剂及其使用方法 Pending CN114641473A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962900869P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
US201962900863P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US62/900,863 2019-09-16
US62/900,860 2019-09-16
US62/900,865 2019-09-16
US62/900,869 2019-09-16
PCT/US2020/050768 WO2021055295A1 (en) 2019-09-16 2020-09-14 Brd9 bifunctional degraders and their methods of use

Publications (1)

Publication Number Publication Date
CN114641473A true CN114641473A (zh) 2022-06-17

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080061458.1A Pending CN114641473A (zh) 2019-09-16 2020-09-14 Brd9双官能团降解剂及其使用方法

Country Status (21)

Country Link
US (1) US20220315578A1 (https=)
EP (1) EP4041724A1 (https=)
JP (1) JP2022547952A (https=)
KR (1) KR20220063192A (https=)
CN (1) CN114641473A (https=)
AU (1) AU2020349451B2 (https=)
BR (1) BR112022003514A2 (https=)
CA (1) CA3153529A1 (https=)
CO (1) CO2022002842A2 (https=)
CR (1) CR20220105A (https=)
DO (1) DOP2022000053A (https=)
EC (1) ECSP22018571A (https=)
IL (1) IL290677A (https=)
JO (1) JOP20220069A1 (https=)
MX (1) MX2022003102A (https=)
PE (1) PE20221417A1 (https=)
PH (1) PH12022550611A1 (https=)
PY (1) PY2054376A (https=)
TW (1) TW202123942A (https=)
UY (1) UY38880A (https=)
WO (1) WO2021055295A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229202A (zh) * 2023-11-15 2023-12-15 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
EP4096651A4 (en) * 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023039208A1 (en) * 2021-09-09 2023-03-16 C4 Therapeutics, Inc. Selected compounds for targeted degradation of brd9
WO2023109892A1 (zh) * 2021-12-15 2023-06-22 海思科医药集团股份有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
WO2024163609A1 (en) * 2023-02-01 2024-08-08 Foghorn Therapeutics Inc. Compositions for treating cancer
KR20260029501A (ko) 2023-05-24 2026-03-04 베액티카 테라퓨틱스 아베 Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025256550A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 靶向降解剂配体及连接基的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
US20180215731A1 (en) * 2017-01-31 2018-08-02 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US11319318B2 (en) * 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
EP3710443A1 (en) * 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP2021506848A (ja) * 2017-12-18 2021-02-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3774808A1 (en) * 2018-03-26 2021-02-17 Novartis AG 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
CN111936498B (zh) * 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3917517A4 (en) * 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) * 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
US20180215731A1 (en) * 2017-01-31 2018-08-02 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VITTORIA ZOPPI ET AL: "Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 2, 12 December 2018 (2018-12-12), pages 699 - 726, XP055564836, DOI: 10.1021/acs.jmedchem.8b01413 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229202A (zh) * 2023-11-15 2023-12-15 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法

Also Published As

Publication number Publication date
AU2020349451B2 (en) 2024-02-01
EP4041724A1 (en) 2022-08-17
KR20220063192A (ko) 2022-05-17
PY2054376A (es) 2021-09-07
PH12022550611A1 (en) 2023-03-13
BR112022003514A2 (pt) 2022-05-17
WO2021055295A1 (en) 2021-03-25
ECSP22018571A (es) 2022-04-29
US20220315578A1 (en) 2022-10-06
JOP20220069A1 (ar) 2023-01-30
AU2020349451A1 (en) 2022-04-21
MX2022003102A (es) 2022-04-06
JP2022547952A (ja) 2022-11-16
PE20221417A1 (es) 2022-09-20
IL290677A (en) 2022-04-01
DOP2022000053A (es) 2023-01-31
CR20220105A (es) 2022-06-13
CO2022002842A2 (es) 2022-04-19
UY38880A (es) 2021-04-30
TW202123942A (zh) 2021-07-01
CA3153529A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CN114641473A (zh) Brd9双官能团降解剂及其使用方法
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
JP7840517B2 (ja) 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN107573332B (zh) 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
CN114521196A (zh) 双官能团降解剂及其使用方法
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
TW202043217A (zh) Ｂｃｌ－２抑制劑
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
JP2024054293A (ja) ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
TW201726606A (zh) 作為免疫調節劑之化合物
WO2020228685A9 (zh) 含氟化合物及抗癌医药用途
TW201041881A (en) Novel thyroid hormone β receptor agonist
JP6954921B2 (ja) ブロモドメイン阻害薬としてのピリジル誘導体
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
JP2018526383A (ja) ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
JP2003529602A (ja) ガランタミンの新規誘導体および類似体
TW202430522A (zh) 一種用於ｂｃｌ－２蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用
WO2025108255A1 (zh) 一种多环类衍生物、其制备方法和应用
CN115960094A (zh) 一类芳香环取代的甲胺衍生物的制备及其用途
WO2025026218A1 (zh) 具有蛋白降解作用的芳胺类化合物
WO2025237389A1 (zh) 三环wrn抑制剂、其制备方法及其应用
HK40061701A (en) Fluorine-containing compound and anti-cancer medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination